Essex Bio-Technology Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Haizhou Fang
Algemeen directeur
HK$1.7m
Totale compensatie
Percentage CEO-salaris | 97.5% |
Dienstverband CEO | no data |
Eigendom CEO | 0.9% |
Management gemiddelde ambtstermijn | 23.8yrs |
Gemiddelde ambtstermijn bestuur | 4.2yrs |
Recente managementupdates
Recent updates
Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement
Oct 09Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | HK$263m |
Mar 31 2024 | n/a | n/a | HK$269m |
Dec 31 2023 | HK$2m | HK$2m | HK$275m |
Sep 30 2023 | n/a | n/a | HK$266m |
Jun 30 2023 | n/a | n/a | HK$256m |
Mar 31 2023 | n/a | n/a | HK$241m |
Dec 31 2022 | HK$2m | HK$2m | HK$225m |
Sep 30 2022 | n/a | n/a | HK$274m |
Jun 30 2022 | n/a | n/a | HK$323m |
Mar 31 2022 | n/a | n/a | HK$334m |
Dec 31 2021 | HK$2m | HK$2m | HK$346m |
Sep 30 2021 | n/a | n/a | HK$339m |
Jun 30 2021 | n/a | n/a | HK$332m |
Mar 31 2021 | n/a | n/a | HK$275m |
Dec 31 2020 | HK$2m | HK$2m | HK$219m |
Sep 30 2020 | n/a | n/a | HK$221m |
Jun 30 2020 | n/a | n/a | HK$222m |
Mar 31 2020 | n/a | n/a | HK$262m |
Dec 31 2019 | HK$2m | HK$737k | HK$303m |
Sep 30 2019 | n/a | n/a | HK$282m |
Jun 30 2019 | n/a | n/a | HK$262m |
Mar 31 2019 | n/a | n/a | HK$246m |
Dec 31 2018 | HK$2m | HK$766k | HK$231m |
Sep 30 2018 | n/a | n/a | HK$210m |
Jun 30 2018 | n/a | n/a | HK$189m |
Mar 31 2018 | n/a | n/a | HK$178m |
Dec 31 2017 | HK$2m | HK$721k | HK$167m |
Compensatie versus markt: De totale vergoeding ($USD 224.15K ) Haizhou } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 336.37K ).
Compensatie versus inkomsten: De vergoeding van Haizhou is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Haizhou Fang (58 yo)
no data
Tenure
HK$1,744,587
Compensatie
Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Founder & Chairman | no data | HK$3.23m | 52.75% HK$ 799.1m | |
MD & Executive Director | no data | HK$1.74m | 0.92% HK$ 14.0m | |
Executive Director & Deputy MD | no data | HK$1.80m | 0.36% HK$ 5.4m | |
Executive Director & Company Secretary | 23.8yrs | HK$755.60k | 0.0081% HK$ 122.9k | |
Group Chief Scientific Officer | 6.6yrs | geen gegevens | geen gegevens |
23.8yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 1061 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 23.8 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Founder & Chairman | no data | HK$3.23m | 52.75% HK$ 799.1m | |
MD & Executive Director | no data | HK$1.74m | 0.92% HK$ 14.0m | |
Executive Director & Deputy MD | 4.2yrs | HK$1.80m | 0.36% HK$ 5.4m | |
Executive Director & Company Secretary | 4.2yrs | HK$755.60k | 0.0081% HK$ 122.9k | |
Independent Non Executive Director | 23.4yrs | HK$250.00k | geen gegevens | |
Independent Non Executive Director | 20.2yrs | HK$220.00k | geen gegevens | |
Independent Non-Executive Director | 1.4yrs | HK$128.33k | geen gegevens |
4.2yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 1061 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).